Eli Lilly and Company (LLY)
Tradepulse Power Inflow Alert: Eli Lilly & Company Moves Up Over 13 Points After Signal
RISES OVER 1.6% AT IT'S HIGH FOR THE DAY AFTER EARLY DROP AND THE POWER INFLOW SIGNAL
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?
One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in the third quarter.
1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock
Conditions are getting a bit more challenging for the drugmaker.
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
The good times aren't over, but the peak of the party might be passing.
Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.
The market's perception of the pharmaceutical company has undeniably shifted.
Eli Lilly Posts a Huge Earnings Miss. Should Investors Be Worried?
Eli Lilly stock has fallen in the days following the release of its latest earnings numbers.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Eli Lilly a Buy? Analyst Confidence Grows for 2025
Eli Lilly's NYSE: LLY market isn't out of the weeds yet but will rebound strongly in 2025. The Q3 results failed to spark a rally because of underperformance, but the salient details are that growth is robust, driving impressive profits, and is expected to accelerate in 2025.
Unlocking Lilly (LLY) International Revenues: Trends, Surprises, and Prospects
Explore Lilly's (LLY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
This Pharma Stock Is Soaring 21%. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo.
Viking said that an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body weight in four weeks.
Analysts revise Eli Lilly stock price targets
Eli Lilly (NYSE: LLY), one of the U.S.'s foremost pharmaceutical giants, faced a sharp 8% drop in its stock price after reporting disappointing third-quarter results, erasing nearly $70 billion from its market value.
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?
Size means little in light of this company's prospects.
